Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Referral and Consultation | 5 | 2023 | 3528 | 0.960 |
Why?
|
Oncology Service, Hospital | 2 | 2017 | 57 | 0.710 |
Why?
|
Carcinoma, Lobular | 2 | 2020 | 484 | 0.620 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 291 | 0.590 |
Why?
|
Physician Assistants | 1 | 2018 | 193 | 0.540 |
Why?
|
Breast Neoplasms | 18 | 2023 | 20817 | 0.540 |
Why?
|
Mammography | 12 | 2018 | 2477 | 0.520 |
Why?
|
Radiology | 4 | 2023 | 2099 | 0.450 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1061 | 0.450 |
Why?
|
Fibrocystic Breast Disease | 5 | 2000 | 102 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 13 | 2023 | 20123 | 0.430 |
Why?
|
Biopsy, Needle | 8 | 2000 | 1640 | 0.380 |
Why?
|
Academic Medical Centers | 5 | 2023 | 2759 | 0.370 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1378 | 0.330 |
Why?
|
Breast | 8 | 2000 | 1969 | 0.320 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 402 | 0.310 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2020 | 143 | 0.300 |
Why?
|
Radiology Information Systems | 3 | 2021 | 523 | 0.300 |
Why?
|
Lymphoma, T-Cell | 1 | 2009 | 299 | 0.290 |
Why?
|
Medical Oncology | 1 | 2018 | 2265 | 0.280 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4252 | 0.280 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4841 | 0.260 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3611 | 0.260 |
Why?
|
Radiology Department, Hospital | 2 | 2019 | 412 | 0.230 |
Why?
|
Ultrasonography, Mammary | 5 | 2018 | 250 | 0.220 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 35423 | 0.220 |
Why?
|
Genes, erbB-2 | 2 | 2014 | 162 | 0.210 |
Why?
|
Stereotaxic Techniques | 5 | 2000 | 535 | 0.200 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2020 | 1101 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2020 | 2017 | 0.190 |
Why?
|
Forms and Records Control | 1 | 2020 | 160 | 0.170 |
Why?
|
Incidental Findings | 2 | 2020 | 689 | 0.160 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2020 | 153 | 0.160 |
Why?
|
Calcinosis | 5 | 2000 | 1499 | 0.150 |
Why?
|
Calcium Phosphates | 1 | 2018 | 171 | 0.150 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2020 | 265 | 0.150 |
Why?
|
Retrospective Studies | 18 | 2023 | 77426 | 0.140 |
Why?
|
Surgical Instruments | 1 | 1999 | 395 | 0.140 |
Why?
|
Workload | 1 | 2002 | 850 | 0.140 |
Why?
|
Tumor Burden | 2 | 2014 | 1914 | 0.140 |
Why?
|
Environment | 1 | 2002 | 1124 | 0.140 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13096 | 0.140 |
Why?
|
Neoplasms | 5 | 2017 | 21672 | 0.140 |
Why?
|
Quality Improvement | 3 | 2020 | 3746 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 901 | 0.130 |
Why?
|
Foreign Bodies | 1 | 1999 | 399 | 0.130 |
Why?
|
Seat Belts | 1 | 1995 | 57 | 0.130 |
Why?
|
Humans | 50 | 2023 | 744220 | 0.130 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6274 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2020 | 921 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1097 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9230 | 0.120 |
Why?
|
Female | 37 | 2023 | 380197 | 0.110 |
Why?
|
Terminology as Topic | 1 | 2020 | 1548 | 0.110 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2416 | 0.110 |
Why?
|
Clinical Protocols | 1 | 2018 | 1462 | 0.110 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2662 | 0.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 949 | 0.100 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2186 | 0.100 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 781 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2017 | 1009 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2013 | 668 | 0.090 |
Why?
|
Quinazolines | 2 | 2014 | 1356 | 0.090 |
Why?
|
Breast Diseases | 3 | 1998 | 443 | 0.090 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2009 | 35 | 0.090 |
Why?
|
Prognosis | 4 | 2019 | 29050 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 607 | 0.090 |
Why?
|
Accidents, Traffic | 1 | 1995 | 819 | 0.080 |
Why?
|
Contrast Media | 3 | 2018 | 5300 | 0.080 |
Why?
|
Survival Analysis | 2 | 2019 | 10250 | 0.080 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 2375 | 0.080 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 166 | 0.080 |
Why?
|
Middle Aged | 25 | 2020 | 213367 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2020 | 11007 | 0.080 |
Why?
|
Aged | 21 | 2020 | 163253 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.080 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 169 | 0.080 |
Why?
|
Nose Neoplasms | 1 | 2009 | 246 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39045 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 450 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1955 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1438 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2014 | 1415 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 895 | 0.070 |
Why?
|
Adult | 21 | 2020 | 214035 | 0.070 |
Why?
|
Melanoma | 2 | 2014 | 5475 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1999 | 3336 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2019 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 5221 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2019 | 57768 | 0.060 |
Why?
|
Carcinoma in Situ | 2 | 2000 | 805 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11493 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2010 | 1178 | 0.050 |
Why?
|
Boston | 3 | 2019 | 9311 | 0.050 |
Why?
|
Mass Screening | 1 | 2018 | 5252 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2525 | 0.050 |
Why?
|
Brachytherapy | 1 | 2010 | 1246 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4564 | 0.050 |
Why?
|
Iohexol | 2 | 2014 | 196 | 0.050 |
Why?
|
Radiography | 2 | 2023 | 7022 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2023 | 8860 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12961 | 0.050 |
Why?
|
Camptothecin | 1 | 2023 | 576 | 0.040 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2005 | 643 | 0.040 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13668 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 284 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
Treatment Outcome | 7 | 2023 | 63119 | 0.040 |
Why?
|
Radiographic Image Enhancement | 2 | 2014 | 885 | 0.040 |
Why?
|
Negotiating | 1 | 2018 | 133 | 0.040 |
Why?
|
Ultrasonography, Interventional | 2 | 2002 | 1483 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4033 | 0.040 |
Why?
|
Male | 11 | 2017 | 350027 | 0.040 |
Why?
|
Radiographic Magnification | 1 | 1996 | 20 | 0.040 |
Why?
|
Axilla | 1 | 2018 | 595 | 0.030 |
Why?
|
Fibroadenoma | 1 | 1996 | 43 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1995 | 58 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 127 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6352 | 0.030 |
Why?
|
Contusions | 1 | 1995 | 81 | 0.030 |
Why?
|
Piperazines | 1 | 2005 | 2491 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9685 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 1999 | 1095 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 1676 | 0.030 |
Why?
|
Data Collection | 1 | 2002 | 3340 | 0.030 |
Why?
|
Pyrimidines | 1 | 2005 | 2940 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 286 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1256 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 574 | 0.030 |
Why?
|
Cysts | 1 | 1997 | 679 | 0.030 |
Why?
|
Vinblastine | 1 | 2013 | 490 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 6535 | 0.020 |
Why?
|
Markov Chains | 1 | 2014 | 969 | 0.020 |
Why?
|
Maytansine | 1 | 2011 | 80 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 1996 | 956 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 1770 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6757 | 0.020 |
Why?
|
Mastectomy | 1 | 2018 | 1793 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3474 | 0.020 |
Why?
|
Ultrasonography | 2 | 2000 | 5982 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5670 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 1996 | 1203 | 0.020 |
Why?
|
Vacuum | 2 | 2000 | 65 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1039 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2726 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1184 | 0.020 |
Why?
|
Risk Factors | 1 | 2014 | 72280 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 53280 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2038 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2886 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4929 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2914 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2014 | 1928 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8663 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 40559 | 0.020 |
Why?
|
Observer Variation | 1 | 2010 | 2593 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3888 | 0.020 |
Why?
|
Survivors | 1 | 2014 | 2291 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2636 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 40063 | 0.010 |
Why?
|
Outpatients | 1 | 2011 | 1486 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1993 | 3469 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 25043 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10949 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5396 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3508 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8343 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10396 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3086 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3311 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1670 | 0.010 |
Why?
|
Benzamides | 1 | 2005 | 1378 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12244 | 0.010 |
Why?
|
Automation | 1 | 2000 | 584 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5529 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 8986 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18367 | 0.010 |
Why?
|
Hyperplasia | 1 | 2000 | 1184 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4599 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2010 | 4044 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8950 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9275 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 19907 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3509 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 20945 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3614 | 0.010 |
Why?
|
Equipment Design | 1 | 2000 | 3582 | 0.010 |
Why?
|
Lung | 1 | 2010 | 9852 | 0.010 |
Why?
|
Young Adult | 1 | 2011 | 56436 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1997 | 21752 | 0.000 |
Why?
|
Adolescent | 1 | 2005 | 85759 | 0.000 |
Why?
|